专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004081531A3 LIGAND ANALYSIS 审中-公开
标题翻译：配对分析
公开(公告)号：WO2004081531A3
公开(公告)日：2006-09-08
申请号：PCT/US2004007364
申请日：2004-03-10
申请人： SCHERING CORP , ANNIS ALLEN D , NASH HUW M , MOALLEMI CIAMAC , LEE WILLIAM H , AKYUZ CAN D , ZHENG ZHONGLI , MAKARA GERGELY M
发明人： ANNIS ALLEN D , NASH HUW M , MOALLEMI CIAMAC , LEE WILLIAM H , AKYUZ CAN D , ZHENG ZHONGLI , MAKARA GERGELY M
IPC分类号： C12Q1/68 , G01N20060101 , G01N33/53 , G01N33/566 , G01N24/00
CPC分类号： G01N33/6848 , C07D307/68 , C07D401/12 , C07D405/14 , C07D413/10
摘要： Methods for the analysis of receptor-ligand pairs are herein described. The methods can provide information about the binding affinity of a ligand to a receptor or can provide information about the binding kinetics of a ligand to a receptor. In some instances, the methods provide a very general system for evaluating and/or optimizing receptor-ligand interactions, which can be applied to a variety of types of receptor-ligand interactions, for example protein-small molecule interactions.
摘要翻译：本文描述了分析受体 - 配体对的方法。该方法可以提供关于配体对受体的结合亲和力的信息，或者可以提供关于配体与受体的结合动力学的信息。在某些情况下，该方法提供了用于评估和/或优化受体 - 配体相互作用的非常通用的系统，其可以应用于多种类型的受体 - 配体相互作用，例如蛋白质 - 小分子相互作用。

2. 发明申请

WO2004081531A8 LIGAND ANALYSIS 审中-公开
标题翻译：配对分析
公开(公告)号：WO2004081531A8
公开(公告)日：2005-10-06
申请号：PCT/US2004007364
申请日：2004-03-10
申请人： SCHERING CORP , ANNIS ALLEN D , NASH HUW M , MOALLEMI CIAMAC , LEE WILLIAM H , AKYUZ CAN D , ZHENG ZHONGLI , MAKARA GERGELY M
发明人： ANNIS ALLEN D , NASH HUW M , MOALLEMI CIAMAC , LEE WILLIAM H , AKYUZ CAN D , ZHENG ZHONGLI , MAKARA GERGELY M
IPC分类号： C12Q1/68 , G01N20060101 , G01N33/53 , G01N33/566 , G01N
CPC分类号： G01N33/6848 , C07D307/68 , C07D401/12 , C07D405/14 , C07D413/10
摘要： Methods for the analysis of receptor-ligand pairs are herein described. The methods can provide information about the binding affinity of a ligand to a receptor or can provide information about the binding kinetics of a ligand to a receptor. In some instances, the methods provide a very general system for evaluating and/or optimizing receptor-ligand interactions, which can be applied to a variety of types of receptor-ligand interactions, for example protein-small molecule interactions.
摘要翻译：本文描述了受体 - 配体对分析方法。该方法可以提供关于配体对受体的结合亲和力的信息，或者可以提供关于配体与受体的结合动力学的信息。在某些情况下，该方法提供了用于评估和/或优化受体 - 配体相互作用的非常通用的系统，其可以应用于多种类型的受体 - 配体相互作用，例如蛋白质 - 小分子相互作用。

3. 发明申请

WO2004081531A9 LIGAND ANALYSIS 审中-公开
标题翻译：配对分析
公开(公告)号：WO2004081531A9
公开(公告)日：2004-10-28
申请号：PCT/US2004007364
申请日：2004-03-10
申请人： NEOGENESIS PHARMACEUTICALS INC , ANNIS ALLEN D , NASH HUW M , MOALLEMI CIAMAC , LEE WILLIAM H , AKYUZ CAN D , ZHENG ZHONGLI
发明人： ANNIS ALLEN D , NASH HUW M , MOALLEMI CIAMAC , LEE WILLIAM H , AKYUZ CAN D , ZHENG ZHONGLI
IPC分类号： C12Q1/68 , G01N20060101 , G01N33/53 , G01N33/566 , G01N
CPC分类号： G01N33/6848 , C07D307/68 , C07D401/12 , C07D405/14 , C07D413/10
摘要： Methods for the analysis of receptor-ligand pairs are herein described. The methods can provide information about the binding affinity of a ligand to a receptor or can provide information about the binding kinetics of a ligand to a receptor. In some instances, the methods provide a very general system for evaluating and/or optimizing receptor-ligand interactions, which can be applied to a variety of types of receptor-ligand interactions, for example protein-small molecule interactions.
摘要翻译：本文描述了受体 - 配体对分析方法。该方法可以提供关于配体对受体的结合亲和力的信息，或者可以提供关于配体与受体的结合动力学的信息。在某些情况下，该方法提供了用于评估和/或优化受体 - 配体相互作用的非常通用的系统，其可以应用于多种类型的受体 - 配体相互作用，例如蛋白质 - 小分子相互作用。

4. 发明申请

WO2004085618A3 METHOD OF SCREENING FOR TARGET LIGANDS 审中-公开
标题翻译：目标配对方法
公开(公告)号：WO2004085618A3
公开(公告)日：2005-09-29
申请号：PCT/US2004008805
申请日：2004-03-22
申请人： SCHERING CORP , NASH HUW M , MASON KEITH , MOALLEMI CIAMAC , WINTNER EDWARD , FLYNN DANIEL , KELLY MICHAEL , ADAMS STEVE , ZHENG ZHONGLI , MAKARA GREG
发明人： NASH HUW M , MASON KEITH , MOALLEMI CIAMAC , WINTNER EDWARD , FLYNN DANIEL , KELLY MICHAEL , ADAMS STEVE , ZHENG ZHONGLI , MAKARA GREG
IPC分类号： C12N20060101 , C12N9/00 , C12N9/12 , C12N15/09 , C12Q1/37 , C12Q1/48 , C12Q1/68 , G01N30/72 , G01N33/00 , G01N33/53 , G01N33/68
CPC分类号： C12Q1/485 , C12N9/12 , G01N30/72 , G01N33/6845 , G01N2500/04 , B01D15/34
摘要： A general system for screening targets (e.g., biomolecules) is described. The screening can be used to discover compounds that bind to a naturally occurring low activity or inactive state of a target and act as inhibitors of the target function as seen in subsequent biological assays.
摘要翻译：描述了用于筛选靶标的一般系统（例如，生物分子）。筛选可以用于发现结合靶的天然存在的低活性或非活性状态的化合物，并且作为靶功能的抑制剂，如随后的生物测定中所见。

5. 发明申请

WO0218540A3 PYRIDINE DERIVATIVES USEFUL AS CD40:CD154 BINDING INTERRUPTOR COMPOUNDS AND USE THEREOF TO TREAT IMMUNOLOGICAL COMPLICATIONS 审中-公开
标题翻译：吡啶衍生物有用的CD40：CD154结合中间体化合物及其用于治疗免疫综合征
公开(公告)号：WO0218540A3
公开(公告)日：2003-12-24
申请号：PCT/US0127361
申请日：2001-08-31
申请人： BIOGEN INC , ZHENG ZHONGLI , CARTER MARY-BETH , LIAO YUSHENG , SUN LIHONG , KIRKOVSKY LEONID , MROSE SUSAN , HSU YEN-MING , DAVID THOMAS , SHIPPS GERALD W JR , JINDAL SATISH , LENZ GEORGE R , NASH HUW M
发明人： ZHENG ZHONGLI , CARTER MARY-BETH , LIAO YUSHENG , SUN LIHONG , KIRKOVSKY LEONID , MROSE SUSAN , HSU YEN-MING , THOMAS DAVID , SHIPPS GERALD W JR , JINDAL SATISH , LENZ GEORGE R , NASH HUW M
IPC分类号： F25B9/00 , A61K31/444 , A61P1/04 , A61P1/16 , A61P9/02 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/06 , A61P19/02 , A61P25/28 , A61P27/02 , A61P29/00 , A61P35/02 , A61P37/00 , A61P37/06 , A61P37/08 , C07C311/47 , C07D401/14 , F25B9/14
CPC分类号： A61K31/444 , C07C311/47 , C07D401/14 , F25B9/10 , F25B9/145 , F25B2309/1408 , F25B2309/1411 , F25B2309/1418 , F25B2309/1424 , F25B2309/14241
摘要： The present invention relates to novel CD40:CD154 binding interruptor compounds of the formula (I), and use of these compounds and pharmaceutical compositions comprising them, to treat conditions associated with inappropriate CD154 activation in a subject. Specifically, this invention provides compounds which are identified by screening a library of small molecules for those that are capable of specifically binding CD154 and interrupting CD40:CD154 interaction.
摘要翻译：本发明涉及式（I）的新型CD40：CD154结合阻断剂化合物，以及包含它们的这些化合物和药物组合物的用途，以治疗与受试者不适当的CD154活化相关的病症。具体地，本发明提供了通过筛选能够特异性结合CD154并中断CD40：CD154相互作用的那些的小分子文库来鉴定的化合物。

6. 发明申请

WO0218446A3 METHODS OF DESIGNING AND PRODUCING COMPOUNDS HAVING IMPROVED BINDING AFFINITY FOR CD154 OR OTHER TRIMERIC PROTEINS 审中-公开
标题翻译：设计和生产具有改善的CD154或其他TRIMERIC蛋白结合亲和力的化合物的方法
公开(公告)号：WO0218446A3
公开(公告)日：2002-05-02
申请号：PCT/US0127360
申请日：2001-08-31
申请人： BIOGEN INC , ZHENG ZHONGLI , TAYLOR FREDERICK R , BENJAMIN CHRISTOPHER D , HSU YEN MING
发明人： ZHENG ZHONGLI , TAYLOR FREDERICK R , BENJAMIN CHRISTOPHER D , HSU YEN-MING
IPC分类号： A61K38/00 , C07K14/705 , C07K16/28 , G01N33/569 , C01N33/554 , A61K39 , A61P37 , C07K16 , G01N33
CPC分类号： C07K16/2875 , A61K38/00 , A61K2039/505 , C07K14/70575 , C07K2319/00 , G01N33/56972 , G01N2333/70575 , G01N2333/70578 , G01N2500/10 , G01N2500/20
摘要： The present invention relates to methods for designing and producing novel CD40:CD154 binding interruptor compounds and methods using these compounds to treat conditions associated with inappropriate CD154 activation in a subject. This invention also relates to novel methods for screening candidate compounds for the properties of specifically binding CD154 and interrupting CD40:CD154 interaction. This invention further relates to methods of improving the binding affinity, or the ability to block CD40/CD154 interaction, of a synthetic molecule for a trimeric protein, such as CD154. These methods comprise converting a first synthetic molecule that cannot promote lattice or aggregate formation of its target trimeric protein to a second synthetic molecule that can promote lattice or aggregate formation of its target trimeric protein. This invention also relates to a two-dimensional lattice or aggregate comprising a plurality of trimeric CD154 on a cell surface or in solution, wherein the lattice or aggregate is formed by bivalent anti-CD154 antibodies associated with trimeric CD154 molecules.
摘要翻译：本发明涉及用于设计和产生新型CD40：CD154结合中断化合物的方法和使用这些化合物治疗与受试者中不适当的CD154活化相关的病症的方法。本发明还涉及用于筛选特异性结合CD154和中断CD40：CD154相互作用的性质的候选化合物的新方法。本发明还涉及提高合成分子对三聚蛋白如CD154的结合亲和力或阻断CD40 / CD154相互作用的能力的方法。这些方法包括将不能促进其目标三聚体蛋白的晶格或聚集体形成的第一合成分子转化成可以促进其目标三聚体蛋白质的晶格或聚集体形成的第二合成分子。本发明还涉及在细胞表面或溶液中包含多个三聚体CD154的二维晶格或聚集体，其中所述晶格或聚集体由与三聚体CD154分子相关的二价抗CD154抗体形成。

7. 发明申请

WO0218445A8 CO-CRYSTAL STRUCTURE OF MONOCLONAL ANTIBODY 5C8 AND CD154, AND USE THEREOF IN DRUG DESIGN 审中-公开
标题翻译：单克隆抗体5C8和CD154的共晶体结构及其在药物设计中的应用
公开(公告)号：WO0218445A8
公开(公告)日：2002-12-27
申请号：PCT/US0127352
申请日：2001-08-31
申请人： BIOGEN INC , KARPUSAS MICHAEL , HSU YEN-MING , TAYLOR FREDERICK R , ZHENG ZHONGLI
发明人： KARPUSAS MICHAEL , HSU YEN-MING , TAYLOR FREDERICK R , ZHENG ZHONGLI
IPC分类号： G01N33/48 , A61K39/395 , A61K45/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P9/10 , A61P11/00 , A61P11/02 , A61P11/04 , A61P11/06 , A61P13/12 , A61P17/04 , A61P17/06 , A61P19/08 , A61P25/00 , A61P25/12 , A61P25/28 , A61P27/02 , A61P29/00 , A61P31/14 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07K14/705 , C07K16/28 , G01N33/15 , G01N33/50 , G01N33/68 , C07K16/00
CPC分类号： C07K16/2875 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/34 , C07K2317/55
摘要： The present invention relates to compositions and crystals of CD154 (CD40L) in complex with an anti-CD154 antibody. In addition, this invention relates to the high resolution structure of a CD154/anti-CD154 antibody complex as obtained by X-ray crystallography. Specifically, this structure provides binding sites defined by the structure coordinates determined herein. This invention also relates to a computer (machine) comprising a machine-readable data storage medium comprising a data storage material encoded with machine-readable data comprising the structure coordinates provided by this invention. The computer has instructions to process said machine-readable data into a three-dimensional representation of a molecular complex of CD154/anti-CD154 antibody based on the structure coordinates provided by this invention. This invention also relates to methods using the structure coordinates of an CD154/anti-CD154 antibody complex to solve the structure of similar or homologous molecular complexes, as well as methods using the structure coordinates of an CD154/anti-CD154 antibody complexto design chemical entities or compounds, including agonists or antagonists of CD154, that specifically bind CD154 and function as CD40:CD154 binding interruptors, as well as to design variants of monoclonal antibody 5c8, or humanized monoclonal antibody 5c8, or antigen binding fragements thereof, having improved properties (such as increased or decreased binding affinity for CD154). This invention also relates to compositions comprising said chemical entities, compounds or variants of monoclonal antibody 5c8 or humanized monoclonal antibody 5c8. The invention further relates to uses of said chemical entities, compounds or variants of monoclonal antibody 5c8 or humanized monoclonal antibody 5c8 to treat a subject having one or more conditons associated with inappropriate or abnormal CD154 induced activation.
摘要翻译：本发明涉及与抗CD154抗体复合的CD154（CD40L）的组合物和晶体。此外，本发明涉及通过X射线晶体学获得的CD154 /抗CD154抗体复合物的高分辨率结构。具体而言，该结构提供由在此确定的结构坐标定义的结合位点。本发明还涉及一种包括机器可读数据存储介质的计算机（机器），该机器可读数据存储介质包括用机器可读数据编码的数据存储材料，该机器可读数据包括由本发明提供的结构坐标。基于本发明提供的结构坐标，计算机具有处理所述机器可读数据为CD154 /抗CD154抗体的分子复合物的三维表示的指令。本发明还涉及使用CD154 /抗CD154抗体复合物的结构坐标来解决相似或同源分子复合物的结构的方法，以及使用CD154 /抗CD154抗体复合物的结构坐标来设计化学实体的方法或化合物（包括CD154的激动剂或拮抗剂），其特异性结合CD154并作为CD40：CD154结合阻断剂，以及设计具有改善特性的单克隆抗体5c8或人源化单克隆抗体5c8或其抗原结合片段的变体（如对CD154的结合亲和力增加或降低）。本发明还涉及包含所述化学实体，单克隆抗体5c8或人源化单克隆抗体5c8的化合物或变体的组合物。本发明进一步涉及单克隆抗体5c8或人源化单克隆抗体5c8的所述化学实体，化合物或变体用于治疗患有一种或多种与不适当或异常CD154诱导活化相关的病症的受试者的用途。

8. 发明申请

WO0218445A9 CO-CRYSTAL STRUCTURE OF MONOCLONAL ANTIBODY 5C8 AND CD154, AND USE THEREOF IN DRUG DESIGN 审中-公开
标题翻译：单克隆抗体5C8和CD154的CO结晶结构及其在药物设计中的应用
公开(公告)号：WO0218445A9
公开(公告)日：2003-03-20
申请号：PCT/US0127352
申请日：2001-08-31
申请人： BIOGEN INC , KARPUSAS MICHAEL , HSU YEN-MING , TAYLOR FREDERICK R , ZHENG ZHONGLI
发明人： KARPUSAS MICHAEL , HSU YEN-MING , TAYLOR FREDERICK R , ZHENG ZHONGLI
IPC分类号： G01N33/48 , A61K39/395 , A61K45/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P9/10 , A61P11/00 , A61P11/02 , A61P11/04 , A61P11/06 , A61P13/12 , A61P17/04 , A61P17/06 , A61P19/08 , A61P25/00 , A61P25/12 , A61P25/28 , A61P27/02 , A61P29/00 , A61P31/14 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07K14/705 , C07K16/28 , G01N33/15 , G01N33/50 , G01N33/68 , G01N33/53 , G06F19/00
CPC分类号： C07K16/2875 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/34 , C07K2317/55
摘要： The present invention relates to compositions and crystals of CD154 (CD40L) in complex with an anti-CD154 antibody. In addition, this invention relates to the high resolution structure of a CD154/anti-CD154 antibody complex as obtained by X-ray crystallography. Specifically, this structure provides binding sites defined by the structure coordinates determined herein. This invention also relates to a computer (machine) comprising a machine-readable data storage medium comprising a data storage material encoded with machine-readable data comprising the structure coordinates provided by this invention. The computer has instructions to process said machine-readable data into a three-dimensional representation of a molecular complex of CD154/anti-CD154 antibody based on the structure coordinates provided by this invention. This invention also relates to methods using the structure coordinates of an CD154/anti-CD154 antibody complex to solve the structure of similar or homologous molecular complexes, as well as methods using the structure coordinates of an CD154/anti-CD154 antibody complexto design chemical entities or compounds, including agonists or antagonists of CD154, that specifically bind CD154 and function as CD40:CD154 binding interruptors, as well as to design variants of monoclonal antibody 5c8, or humanized monoclonal antibody 5c8, or antigen binding fragements thereof, having improved properties (such as increased or decreased binding affinity for CD154). This invention also relates to compositions comprising said chemical entities, compounds or variants of monoclonal antibody 5c8 or humanized monoclonal antibody 5c8. The invention further relates to uses of said chemical entities, compounds or variants of monoclonal antibody 5c8 or humanized monoclonal antibody 5c8 to treat a subject having one or more conditons associated with inappropriate or abnormal CD154 induced activation.
摘要翻译：本发明涉及与抗CD154抗体复合的CD154（CD40L）的组合物和晶体。此外，本发明涉及通过X射线晶体学获得的CD154 /抗-CD154抗体复合物的高分辨率结构。具体地，该结构提供了由本文确定的结构坐标限定的结合位点。本发明还涉及一种计算机（机器），其包括机器可读数据存储介质，其包括用包括由本发明提供的结构坐标的机器可读数据编码的数据存储材料。计算机具有基于本发明提供的结构坐标将所述机读数据处理成CD154 /抗-CD154抗体分子复合物的三维表示的指令。本发明还涉及使用CD154 /抗CD154抗体复合物的结构坐标来解决类似或同源分子复合物的结构的方法，以及使用CD154 /抗-CD154抗体复合物的结构坐标设计化学实体的方法或包含CD154的特异性结合CD154和作为CD40：CD154结合中断的功能的CD154的激动剂或拮抗剂的化合物，以及设计具有改善性质的单克隆抗体5c8或其抗原结合残基的变体，例如增加或降低对CD154的结合亲和力）。本发明还涉及包含单克隆抗体5c8或人源化单克隆抗体5c8的所述化学实体，化合物或变体的组合物。本发明还涉及所述化学实体，单克隆抗体5c8或人源化单克隆抗体5c8的化合物或变体的用途来治疗具有与不适当或异常CD154诱导的活化相关的一个或多个条件的受试者。

9. 发明公开

EP1606399A4 METHOD OF SCREENING FOR TARGET LIGANDS 审中-公开
标题翻译：一种筛选目标配体
公开(公告)号：EP1606399A4
公开(公告)日：2006-08-02
申请号：EP04758048
申请日：2004-03-22
申请人： SCHERING CORP
发明人： NASH HUW M , MASON KEITH , MOALLEMI CIAMAC , WINTNER EDWARD , FLYNN DANIEL , KELLY MICHAEL , ADAMS STEVE , ZHENG ZHONGLI , MAKARA GREG
IPC分类号： C12N20060101 , C12N9/00 , C12N9/12 , C12N15/09 , C12Q1/37 , C12Q1/48 , C12Q1/68 , G01N30/72 , G01N33/00 , G01N33/53 , G01N33/68
CPC分类号： C12Q1/485 , C12N9/12 , G01N30/72 , G01N33/6845 , G01N2500/04 , B01D15/34

10. 发明公开

EP1631810A4 LIGAND ANALYSIS 审中-公开
标题翻译：配体分析
公开(公告)号：EP1631810A4
公开(公告)日：2008-11-05
申请号：EP04719270
申请日：2004-03-10
申请人： SCHERING CORP
发明人： ANNIS ALLEN D , NASH HUW M , MOALLEMI CIAMAC , LEE WILLIAM H , AKYUZ CAN D , ZHENG ZHONGLI , MAKARA GERGELY M
IPC分类号： G06F19/00 , C12Q1/68 , G01N20060101 , G01N24/00 , G01N33/53 , G01N33/566 , G01N33/68
CPC分类号： G01N33/6848 , C07D307/68 , C07D401/12 , C07D405/14 , C07D413/10
摘要： Methods for the analysis of receptor-ligand pairs are herein described. The methods can provide information about the binding affinity of a ligand to a receptor or can provide information about the binding kinetics of a ligand to a receptor. In some instances, the methods provide a very general system for evaluating and/or optimizing receptor-ligand interactions, which can be applied to a variety of types of receptor-ligand interactions, for example protein-small molecule interactions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式